http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#Head http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#assertion http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#provenance http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#pubinfo http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#assertion http://purl.obolibrary.org/obo/DOID_9074 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_9074 http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB08879 http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association http://www.w3.org/2000/01/rdf-schema#label benlysta belimumab is indicated for the treatment of patients aged 5 years and older with active autoantibody positive systemic lupus erythematosus sle who are receiving standard therapy limitations of use the efficacy of benlysta has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus benlysta has not been studied in combination with other biologics or intravenous cyclophosphamide use of benlysta is not recommended in these situations benlysta is a b lymphocyte stimulator blys specific inhibitor indicated for the treatment of patients aged 5 years and older with active autoantibody positive systemic lupus erythematosus who are receiving standard therapy 1 limitations of use the efficacy of benlysta has not been evaluated in patients with severe active lupus nephritis or severe active central nervous system lupus benlysta has not been studied in combination with other biologics or intravenous cyclophosphamide use of benlysta is not recommended in these situations 1 http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB08879 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#provenance http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#pubinfo http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#sig http://purl.org/nanopub/x/hasSignature RsG4q6KCP+7vJcZ+tdsV/cftvRGFAD5uwZ4IDUsLdCxrm7y0FwP2kII4umvQ5oWf6+kawHrIcWKviTre5y6EmU6eSV9Y79F1hEDdYJ59sw9eyXIV/qtm56FOV9H89p2ssGcIjgrG9h9lpempNEA2THPw8W6+/uAFFC4Tb2vvHgU= http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M http://purl.org/dc/terms/created 2021-07-03T14:55:22.169+02:00 http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAL6CgExAulYiEjFfdIFVWQ8P0NQlGSVWLcf9Mbw60K8M https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs